Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 12, 2010, Pages 1723-1731

  Krüger, Ralf ^a   Vogeser, Michael ^b   Burghardt, Stephan ^c   Vogelsberger, Rita ^a   Lackner, Karl J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Chromsystems GmbH   (Germany)

Author keywords

glucuronide; interference; liquid chromatography tandem mass spectrometry (LC MS MS); metabolite; posaconazole; therapeutic drug monitoring; ultra perfor mance liquid chromatography (UPLC)

Indexed keywords

ANTIFUNGAL AGENT; GLUCURONIDE; HYDROXYITRACONAZOLE; ITRACONAZOLE; POSACONAZOLE; R 051012; SCH 56984; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CALIBRATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DETERMINATION; DRUG MONITORING; DRUG STRUCTURE; FLUORESCENCE ANALYSIS; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; SIGNAL NOISE RATIO; STANDARD; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTIFUNGAL AGENTS; DRUG MONITORING; GLUCURONIDES; HUMANS; OBSERVER VARIATION; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 78650630836     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.333     Document Type: Article

References (32)

1. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit, 2008; 30: 167-72.
2. Worth LJ, Blyth CC, Booth DL, Kong DC, Marriott D, Cassumbhoy M, et al. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Int Med J 2008;38:521-37.
3. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008;61:17-25.
4. Cox SK, Orosz S, Burnette J, Frazier D. Microassay for determination of itraconazole and hydroxyitraconazole in plasma and tissue biopsies. J Chromatogr B 1997;702:175-80.
5. Gubbins PA, Gurley BJ, Bowman J. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J Pharm Biomed Anal 1998;16:1005-12.
6. Koks CH, Sparidans RW, Lucassen G, Crommentuyn KM, Beijnen JH. Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. J Chromatogr B 2002;767:103-10.
7. Redmann S, Charles BG. A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxyitraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis. Biomed Chromatogr 2006;20:343-8.
8. Keevil BG, Newman S, Lockhart S, Howard SJ, Moore CB, Denning DW. Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2004;26:650-7.
9. Egle H, Trittler R, König A, Kümmerer A. Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique. J Chromatogr B 2005; 814:361-7.
10. Vogeser M, Schiel X, Spöhrer U. Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2005;43:730-4.
11. Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B 2007;852:223-8.
12. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85.
13. Nagappan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-7.
14. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
15. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403.
16. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41: 3623-6.
17. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
18. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
19. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt P, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
20. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22.
21. Kim H, Kumari P, Laughlin M, Hilbert MJ, Indelicato SR, Lim J, et al. Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma. J Chromatogr A 2003;987:243-8.
22. Störzinger D, Swoboda S, Lichtenstern C, Müller C, Weigand MA, Hoppe-Tichy T. Development and validation of a highperformance liquid chromatography assay for posaconazole utilizing solid-phase extraction. Clin Chem Lab Med 2008; 46:1747-51.
23. Neubauer W, König A, Bolek R, Trittler R, Engelhardt M, Jung M, et al. Determination of the antifungal agent posaconazole in human serum by HPLC with parallel column-switching technique. J Chromatogr B 2009;877:2493-8.
24. Feng W, Liu H, Chen G, Malchow R, Bennett F, Lin E, et al. Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS. J Pharm Biomed Anal 2001;25:545-57.
25. Krieter P, Flannery B, Musick T, Gohdes M. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51.
26. Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-36.
27. Shen JX, Tama CI, Hayes RN. Evaluation of automated micro solid phase extraction tips (m-SPE) for the validation of a LC-MS/MS bioanalytical method. J Chromatogr B 2006; 843:275-82.
28. Vogeser M, Rieger C, Ostermann H, Spöhrer U. A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2009;47:579-84.
29. Cunliffe JF, Noren CF, Hayes RN, Clement RP, Shen JX. A high-throughput LC-MS/MS method for the quantitation of posaconazole in human plasma: implementing fused core silica liquid chromatography. J Pharm Biomed Anal 2009;50:46-52.
30. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32: 267-71.
31. Vogeser M, Zachoval R, Spöhrer U, Jacob K. Potential lack of specificity using electrospray tandem-mass spectrometry for the analysis of mycophenolic acid in serum. Ther Drug Monit 2001;23:722-4.
32. Kuhn J, Prante C, Kleesiek K, Götting C. Measurement of mycophenolic acid and its glucuronide using a novel rapid liquid chromatography-electrospray ionization tandem mass spectrometry assay. Clin Biochem 2009;4283-90.